Deadline
Passed
Lead Plaintiff Deadline: June 02, 2021
Please Upload related files below
Fill in below.
Tell us the stocks you own using Snaptrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. Snaptrade only shares the tickers you own and your transaction history, not your account numbers. Using Snaptrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.
Don’t miss out on possible monetary recovery- link your account with Snaptrade.
01
Oct 2020
10
Mar 2021
(i) the Belumosudil NDA was incomplete and/or deficient; (ii) the additional new data that the Company submitted in support of the Belumosudil NDA in response to an information request from the FDA materially altered the NDA submission; (iii) accordingly, the initial Belumosudil NDA submission lacked the degree of support that the Company had led investors to believe; (iv) accordingly, the FDA was likely to extend the PDUFA target action date to review the Belumosudil NDA; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.
In order to be included in the lawsuit, you must have incurred a loss on shares of Kadmon Holdings purchased during the class period listed above.
If you suffered a loss in Kadmon Holdings during the relevant time frame, you have until June 02, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.